Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Disorders, Lymphoproliferative”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Not applicableEnrolling By InvitationNCT02473757
What this trial is testing

Gene Therapy Follow-up Protocol for People Previously Enrolled in CAR-T Cell Studies

Who this might be right for
Lyphoma, B-CellLeukemia, B-cellMultiple Myeloma+1 more
National Cancer Institute (NCI) 1,000
Testing effectiveness (Phase 2)Active Not RecruitingNCT04439201
What this trial is testing

Testing Palbociclib (PD-0332991) as a Potential Targeted Treatment in Cancers With CCND1, 2, 3 Amplification (MATCH-Subprotocol Z1B)

Who this might be right for
Advanced LymphomaAdvanced Malignant Solid NeoplasmHematopoietic and Lymphoid Cell Neoplasm+2 more
National Cancer Institute (NCI) 40
Testing effectiveness (Phase 2)Study completedNCT02499081
What this trial is testing

UARK 2014-14: Phase II Prospective Evaluation of Bone Remodeling During Ixazomib Treatment

Who this might be right for
Multiple Myeloma
University of Arkansas 20
Not applicableStudy completedNCT03344328
What this trial is testing

Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.

Who this might be right for
Chemotherapy Induced Peripheral NeuropathyMultiple Myeloma
University Hospital, Clermont-Ferrand 67
Testing effectiveness (Phase 2)Looking for participantsNCT07494565
What this trial is testing

Celecoxib Plus R-CHOP vs R-CHOP in Newly Diagnosed Advanced CD5+ DLBCL

Who this might be right for
Diffuse Large B-Cell Lymphoma (DLBCL)CD5 Positive
Sun Yat-sen University 60
Testing effectiveness (Phase 2)Looking for participantsNCT04560322
What this trial is testing

Venetoclax-Obinutuzumab +/- Acalabrutinib in R/R CLL

Who this might be right for
Chronic Lymphocytic LeukemiaSmall Lymphocytic Lymphoma
Massachusetts General Hospital 40
Testing effectiveness (Phase 2)Study completedNCT00737529
What this trial is testing

Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

Who this might be right for
Mantle Cell Lymphoma
Celgene 134
Large-scale testing (Phase 3)Ended earlyNCT01662102
What this trial is testing

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

Who this might be right for
Follicular Lymphoma
Spectrum Pharmaceuticals, Inc 1
Large-scale testing (Phase 3)Study completedNCT00137995
What this trial is testing

R-ICE Versus R-DHAP in Patients Aged 18-65 With Relapse Diffuse Large B-cell Lymphoma

Who this might be right for
Lymphoma, Large-Cell, Diffuse
Lymphoma Study Association 481
Testing effectiveness (Phase 2)Looking for participantsNCT04083495
What this trial is testing

CD30 CAR for Relapsed/Refractory CD30+ T Cell Lymphoma

Who this might be right for
Peripheral T Cell Lymphoma
UNC Lineberger Comprehensive Cancer Center 20
Early research (Phase 1)Study completedNCT03003039
What this trial is testing

A Study Comparing GB241 And Rituximab in Patients With B-cell Non-Hodgkin's Lymphoma

Who this might be right for
B-Cell Lymphoma
Nanjing Yoko Biomedical Co., Ltd. 85
Large-scale testing (Phase 3)Study completedNCT00088530
What this trial is testing

BBR 2778 for Relapsed, Aggressive Non-Hodgkin's Lymphoma (NHL)

Who this might be right for
Lymphoma, Non-Hodgkin
CTI BioPharma 140
Early research (Phase 1)Active Not RecruitingNCT05646836
What this trial is testing

Evaluate the Safety, Pharmacokinetics, and Activity of XmAb24306 in Combination With Cevostamab in Participants With Relapsed/Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Genentech, Inc. 90
Testing effectiveness (Phase 2)Study completedNCT00005631
What this trial is testing

Rituximab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Large Cell Lymphoma

Who this might be right for
Lymphoma
Memorial Sloan Kettering Cancer Center
Testing effectiveness (Phase 2)Looking for participantsNCT06863402
What this trial is testing

Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype

Who this might be right for
Richter SyndromeDiffuse Large B-Cell LymphomaChronic Lymphocytic Leukemia
Roswell Park Cancer Institute 32
Testing effectiveness (Phase 2)Study completedNCT00027937
What this trial is testing

Combination Chemotherapy, Peripheral Stem Cell Transplantation, and Biological Therapy in Treating Patients With Solid Tumors or Lymphoma

Who this might be right for
LymphomaUnspecified Adult Solid Tumor, Protocol SpecificUnspecified Childhood Solid Tumor, Protocol Specific
Fred Hutchinson Cancer Center
Not applicableNot Yet RecruitingNCT07008872
What this trial is testing

CD7 CAR-T Cell Therapy Targeting CD7-positive Relapsed/Refractory T Cell Lymphoma/Acute Leukemia

Who this might be right for
CD7+ LymphomaCD7+ Acute Leukemia
Qi deng 40
Not applicableUnknownNCT00416377
What this trial is testing

Radiation Therapy or Combination Chemotherapy in Treating Young Patients With Hodgkin's Lymphoma

Who this might be right for
Lymphoma
Children's Cancer and Leukaemia Group 353
Early research (Phase 1)Study completedNCT00996957
What this trial is testing

Study of ACE-041 in Patients With Advanced Solid Tumors or Relapsed/Refractory Multiple Myeloma

Who this might be right for
Advanced Solid TumorsMultiple Myeloma
Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA 37
Testing effectiveness (Phase 2)Active Not RecruitingNCT04278781
What this trial is testing

AG-120 in People With IDH1 Mutant Chondrosarcoma

Who this might be right for
ChondrosarcomaChondrosarcoma, Grade 2Chondrosarcoma, Grade 3+1 more
Memorial Sloan Kettering Cancer Center 6
Next Page